SentryX closes €3.2M seed funding round for the development of next generation pain relief therapeutics

We are delighted with the new investment in SentryX, a next generation, innovative pain relief therapy platform, focusing on orthopedic surgical post-procedural pain. Press release: June 9, 2021 – Utrecht, the Netherlands SentryX, a spin-off of the University Medical Center Utrecht (the Netherlands) today announced that it raised €3.2M in seed funding

TargED Biopharmaceuticals appoints Ludo Haazen, M.D. as Chief Medical Officer

TargED Biopharmaceuticals, a biotech spin-off of the University Medical Center Utrecht, today announced the appointment of Ludo Haazen as Chief Medical Officer (CMO). Kristof Vercruysse, CEO of TargED commented: “We are delighted that Ludo is joining our team as CMO. In Ludo, we found the ideal candidate to support the

NTrans Technologies closes Series A investment to accelerate development of gene editing therapy

We’re excited to be investing in NTrans Technologies BV, a gene editing therapy company focusing on Duchenne Muscular Dystrophy, together with Essential Ventures, BOP Capital and Starfish Innovations. May 27, 2021 Utrecht, The Netherlands – NTrans Technologies (NTrans), a leader in gene editing technologies, today announced a Series A investment

Moveshelf closes seed investment to accelerate digital transformation of diagnosis and care for movement disorders

We proudly announce UHSF’s second investment, in Moveshelf, together with Locapes Investment Fund. Moveshelf is a digital health company with a unique platform for clinical movement analysis. We look forward to working with their talented team! Please find the press release below: March 2nd, 2021, Utrecht, The Netherlands   Moveshelf, a

TargED receives NWO Take-Off 2

Congratulations to the team of our portfolio company TargED Biopharmaceuticals, as they have been awarded a Take-Off 2 grant from NWO (the Dutch National Science Organization)!

TargED closes seed investment and partners with UMC Utrecht for the development of Microlyse – a next-generation thrombolytic clot-busting drug

We’re thrilled to announce UHSF’s first investment, in TargED Biopharmaceuticals, together with Curie Capital and FIRST Fund. TargED is developing a next generation clot-busting drug with unique properties, initially focusing on acute ischemic stroke as its target, with several thrombotic diseases as potential spin-offs. Please find the press release below: TargED closes seed

ROM Regio Utrecht Launched

The Regional Development Fund (Regionale Ontwikkelingsmaatschappij or ROM) for the region of Utrecht is launched. The ROM Regio Utrecht Fund aims to strengthen the economic structure and innovation power of the Utrecht region. We at the Utrecht Health Seed Fund (UHSF) look forward to collaborating with the ROM in the

New Utrecht-based fund investing in Life Science & Health start-ups

The Utrecht Health Seed Fund (UHSF) officially launched at the end of March. Over the next three years, it’ll be looking to invest in promising start-ups based in the province of Utrecht and working in the field of Life Sciences & Health (LS&H). Jaap de Bruin (UHSF Fund Manager) explains the reasons for setting up the UHSF, “Utrecht is

Nieuws

SentryX closes €3.2M seed funding round for the development of next generation pain relief therapeutics

We are delighted with the new investment in SentryX, a next generation,…

TargED Biopharmaceuticals appoints Ludo Haazen, M.D. as Chief Medical Officer

TargED Biopharmaceuticals, a biotech spin-off of the University…

NTrans Technologies closes Series A investment to accelerate development of gene editing therapy

We're excited to be investing in NTrans Technologies BV, a gene…

Moveshelf closes seed investment to accelerate digital transformation of diagnosis and care for movement disorders

We proudly announce UHSF's second investment, in Moveshelf, together…

TargED receives NWO Take-Off 2

Congratulations to the team of our portfolio company TargED Biopharmaceuticals,…